Clinical Trials · NCT02436447
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 23
- Start date
- May 2015
- Locations
- 1 site, United States
- Primary endpoint
- Mean peak plasma concentration (Cmax) of MTP-131 (ng/ml) in each cohort